Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma

Pach, Jolanta; Olamiju, Brianna; Weiss, Sarah A.; Damsky, William; Leventhal, Jonathan S.

doi:10.1001/jamadermatol.2021.0058

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

2023

Publication Types

Select...

Article3

Preprint1

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, there are only 2 cases of fat necrosis associated with these agents that are reported in the literature that similarly manifested on the bilateral lower extremities, however, imaging results or histologic images and survival data were not presented in that two article [4,5].…”

Section: Discussionmentioning

confidence: 99%

Subcutaneous Fat Necrosis During Pembrolizumab Therapy for Metastatic Gastric Cancer: Case Report and Review of the Literature

Zhao

Lin

2022

Preprint

View full text Add to dashboard Cite

Background： Recent evidence suggests that immunotherapy is a standard treatment options in gastric cancer. However, immunotherapy may cause many known or unknown adverse events. Case presentation: We recently encountered a case of subcutaneous fat necrosis without pancreatic disease that arose during therapy with pembrolizumab in a patient with metastatic gastric cancer. And subcutaneous nodules started to spontaneously improve within a month of onset and disappeared within half a year with no special treatment. At the last follow-up, the patient did not receive immunotherapy with continuous stable disease. Her survival exceeded 24 months without other treatment. Conclusion: This case may be important for the discovery of rare adverse events in gastric cancer immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%